This report was finalized prior to a significant development affecting its central thesis. On July 17, 2026, GSK discontinued the Phase III program for camlipixant — the asset identified throughout this report as the leading candidate for first FDA approval in refractory chronic cough. Readers should take this into account.
Pipeline Analysis & Competitive Landscape 2026–2035
Refractory Chronic Cough remains a large, undertreated, and globally unaddressed condition. The first U.S. approval—expected no earlier than 2026—will create a new therapeutic category.
~100M affected worldwide with no FDA-approved therapies. Current practice relies on off-label medicines with 31–40% adverse event rates and modest efficacy.
Two Complete Response Letters for Gefapixant raised the bar: FDA now requires ≥30% placebo-adjusted reduction in objective 24-hour cough frequency.
Camlipixant leads with ~34% efficacy and <7% taste AEs. Nalbuphine ER shows highest efficacy (60% reduction). The U.S. market will likely see one winner, at most two.
Digital therapeutics deliver ~40% cough reduction with no drug toxicity and extend pharmacologic persistence by 30%, improving lifetime value by ~44%.
"Therapies capable of demonstrating ≥30% placebo-adjusted efficacy, low discontinuation, durable symptom control, and digital integration will dominate the market and define the first generation of approved RCC treatments."
Refractory chronic cough (RCC) is a cough lasting more than eight weeks that persists despite guideline-based treatment of its underlying causes. It is associated with cough hypersensitivity syndrome and affects an estimated 100 million people worldwide, including roughly 10 million in the United States.
As of July 2026, there are no FDA-approved therapies for RCC in the United States. Current care relies on off-label medicines that carry high adverse-event rates and offer only modest efficacy.
On July 17, 2026, GSK discontinued the Phase III development program for camlipixant in RCC after the CALM-1 and CALM-2 trials produced mixed results and, per GSK, limited efficacy unlikely to transform patient care. Camlipixant had been the most advanced pipeline asset and the leading candidate for the first FDA approval in RCC. Its discontinuation leaves the indication without a late-stage P2X3 antagonist in active development. See the Publisher's Note for details.
The RCC therapeutics market is estimated at approximately $9–10 billion in 2024–2025 and is projected to reach roughly $15–18.5 billion by 2035, a compound annual growth rate of about 6%.
Following two Complete Response Letters for gefapixant, the FDA expects at least a 30% placebo-adjusted reduction in objective 24-hour cough frequency, together with clinically meaningful improvements in patient-reported outcomes.
Digital and behavioral cough suppression therapy can deliver roughly 40% cough reduction on its own. Combined with pharmacologic treatment, it can extend treatment persistence by about 30% and improve patient lifetime value by around 44%.
Enter your email to unlock the complete 52-page analysis including pipeline scorecards, scenario models, risk matrices, and strategic positioning insights.
By submitting, you agree to receive the report and occasional updates. We respect your privacy and will never share your information.
The chronic cough market is valued at approximately $9.8B in 2024 across the 7 Major Markets, projected to reach $14.9B by 2035 (CAGR ~6%).
Aging populations, specialist referral expansion, digital identification tools, and increasing recognition of cough hypersensitivity syndrome are driving market growth.
Zero approved drugs for RCC in the U.S. creates first-mover advantage opportunity.
GSK's $2B acquisition of Bellus Health validates the market opportunity.
~$14B+ projected market with 31% of patients failing all current treatments.
The RCC treatment market is projected to grow from $10.4B in 2025 to $18.5B by 2035, representing a CAGR of approximately 5.9% globally.
| Region | CAGR |
|---|---|
| United States | 6.4% |
| South Korea | 6.2% |
| European Union | 6.0% |
| United Kingdom | 5.8% |
| Japan | 5.7% |
Efficacy: >30% cough reduction (placebo-adjusted)
Tolerability: Taste AEs <10%
Durability: 24–52 weeks without tachyphylaxis
Phase 2b SOOTHE trial demonstrated 34.4% reduction at 50mg BID with only 6.5% taste AEs—meeting all three success criteria.
| Mechanism | Adj. Efficacy | Key AEs |
|---|---|---|
| P2X3 (Camlipixant) | 34% | 6.5% taste |
| KOR/MOR (Nalbuphine) | 43-57% | Nausea, sedation |
| Digital BCST | 41% | None |
| P2X3 (Gefapixant) | 14-19% | 50-81% taste |
Without stronger HEOR evidence, even efficacious therapies may see restricted access or price compression. Key barriers include high OOP costs, step therapy requirements, and geographic SLP access limitations.
Median time to diagnosis: 6.5 years
60% see ≥1 specialist
57% prescribed ≥4 medications
49% see ≥4 physicians before diagnosis
| Asset | Stage | Next Milestone |
|---|---|---|
| Camlipixant (GSK) | Phase 3 | CALM-1/2 H2 2025 |
| Nalbuphine ER (Trevi) | Phase 2b | Phase 3 H1 2026 |
| Taplucainium (Nocion) | Phase 2b | Topline 2025-26 |
| Hyfe DTx (Kyorin) | Pre-launch | Japan 2027 |
60-85% placebo response rate complicates clinical development. Gefapixant Phase 3 showed only 6.9% absolute difference vs active in responder rates.
Average duration: 7 months → 9.1 months (+30%)
Revenue/patient: $7,700 → $10,010 (+30%)
LTV (3-year): $15,400 → $22,110 (+44%)
ROI: 7.7:1
Digital integration delivers +$1.57B value lift (+20%) in base case scenario.
Get the full 52-page PDF with all exhibits, data tables, and detailed analysis.
Download PDF